Your browser doesn't support javascript.
loading
Cytotoxic profile of CD3+CD20+ T cells in progressive multiple sclerosis.
Boldrini, Vinícius O; Quintiliano, Raphael P S; Silva, Lucas S; Damasceno, Alfredo; Santos, Leonilda M B; Farias, Alessandro S.
Afiliação
  • Boldrini VO; Autoimmune Research Lab., Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil; Neuroimmunology Unit, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil; Nationa
  • Quintiliano RPS; Neuroimmunology Unit, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.
  • Silva LS; Department of Neurology, University of Campinas, Campinas, Brazil.
  • Damasceno A; Department of Neurology, University of Campinas, Campinas, Brazil.
  • Santos LMB; Autoimmune Research Lab., Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil; Neuroimmunology Unit, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil; Nationa
  • Farias AS; Autoimmune Research Lab., Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil; Neuroimmunology Unit, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil; Nationa
Mult Scler Relat Disord ; 52: 103013, 2021 Jul.
Article em En | MEDLINE | ID: mdl-34030100
ABSTRACT
Recently, it was shown that highly effective anti-CD20 therapies used for MS patients not only deplete CD20+ B cells, but also a small subset of T cells expressing CD20 surface marker (CD3+CD20+ T cells). Here we demonstrated that, in progressive MS patients, CD3+CD20+ T cells share the ability to express cytotoxic factors such as perforin and serine-protease granzyme-B (GzmB), classically associated with CD8+ T cells functionality. Beyond it, cluster analyses show that a set of activation markers and transcriptional factors related with CD8 effector program are also expressed in CD3+CD20+ T cells. Further characterization of surface and functional markers from CD3+CD20+ T subsets may be helpful for development of new therapeutic strategies mainly for progressive MS patients, as well as for assessing pathophysiological effects of highly effective anti-CD20 therapies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article